This work was presented at the Third Bernese SIOPEL Workshop, on April 5, 2001.
Article first published online: 12 SEP 2002
Copyright © 2002 Wiley-Liss, Inc.
Medical and Pediatric Oncology
Special Issue: Proceedings of the Third SIOPEL Liver Tumour Study Group Workshop
Volume 39, Issue 5, pages 484–486, November 2002
How to Cite
Finegold, M. J. (2002), Chemotherapy for suspected hepatoblastoma without efforts at surgical resection is a bad practice. Med. Pediatr. Oncol., 39: 484–486. doi: 10.1002/mpo.10172
The author has no financial or other self-serving interest in the matters presented other than the advancement of therapy for afflicted children.
- Issue published online: 12 SEP 2002
- Article first published online: 12 SEP 2002
- treatment of hepatoblastoma;
- chemotherapy toxicity
US and European practices differ with respect to treating hepatoblastoma (HB). Should chemotherapy be given prior to resection in all cases, and even without biopsy confirmation (SIOPEL)?
Procedure and Results
US data indicate that 40% of HBs are primarily resectable with no operative mortality and that those with pure fetal histology and low mitotic rate do not require toxic chemotherapy. They also suggest that those with a significant fraction of small undifferentiated cells do not respond to otherwise effective chemotherapy. Both US and European studies report a significant error rate in the clinical and imaging diagnosis of HB.
Although only 6.5% of confirmed HBs fall into categories that would be managed differently by US standards, there is no justification for denying those patients a more appropriate treatment nor should the 6–10% of cases that are misdiagnosed as HB be treated incorrectly. Med Pediatr Oncol 2002;39:484–486. © 2002 Wiley-Liss, Inc.